Introduction {#s1}
============

Breast cancer is the most commonly diagnosed cancer and a predominate cause of death in female population worldwide [@pone.0061662-Parkin1]. Although many risk factors for breast cancer have been identified, such as the genetic predisposition and estrogen level, the molecular mechanisms related to breast carcinogenesis remain under investigation [@pone.0061662-Yager1], [@pone.0061662-Veronesi1].

The *p53* tumor suppressor gene, designated as the guardian of the genome, is the most frequently mutated gene in different types of cancers [@pone.0061662-Hollstein1]. It is reported that the *p53* gene is mutated in 20%--30% of the sporadic breast cancer [@pone.0061662-Hainaut1]. These mutations can affect the functions of p53 protein as a transcription factor, and consequently many crucial functions such as DNA repair, cell cycle control, and apoptosis may be altered. Besides mutations, many single nucleotide polymorphisms (SNPs) have been identified in *p53* gene. The most informative one is the codon 72 Arg\>Pro polymorphism (rs1042522), which results in structural alteration of the p53 protein and consequently affect its functions [@pone.0061662-Dumont1]. To date, the SNP rs1042522 has been found to be associated with risk of various cancers, including breast cancer, in different populations [@pone.0061662-Klug1]--[@pone.0061662-Zhang1]. Moreover, the *p53* gene also contains several polymorphisms in non-coding region. Among these, the 16-bp duplication polymorphism (rs17878362) within intron 3 has been widely analyzed as possible cancer susceptibility modifiers ([Figure 1](#pone-0061662-g001){ref-type="fig"}). Gemignani *et al.* [@pone.0061662-Gemignani1] found that the 16-bp Ins allele led to lower level of *p53* transcript, suggesting that this polymorphism causes an alteration in mRNA processing, which provides a possible molecular basis for the associated increased risk of developing cancer.

![Gene structure of *P53* gene and location of intron 3 16-bp duplication polymorphism (rs17878362).](pone.0061662.g001){#pone-0061662-g001}

Over the last two decades, a number of case-control studies were conducted to investigate the association between the SNP rs17878362 and breast cancer risk. But these studies reported conflicting results. Since a single study might have been underpowered to detect the overall effects, a quantitative synthesis of the pooled data from different studies was deemed important to provide evidence for this association.

Thus, we carried out a meta-analysis on all eligible case-control studies to estimate the overall breast cancer risk of *p53* intron 3 duplication polymorphism as well as to quantify the between-study heterogeneity and potential bias.

Materials and Methods {#s2}
=====================

Literature search and data extraction {#s2a}
-------------------------------------

To identify all studies that examined the association of *p53* intron 3 duplication polymorphism with breast cancer risk, we conducted a literature search of the PubMed and Embase database without a language limitation (the last search update was September 15, 2012, using the search terms "p53", "polymorphism", "variant", and "breast cancer"). Review articles were hand-searched to find additional eligible studies and only published studies with full-text articles were included. Studies included in our meta-analysis have to meet the following criteria: (1) use a case-control design and (2) contain available genotype frequency. Major reasons for exclusion of studies were: (1) genotype frequency was not reported (2) duplicate of previous publication and (3) abstract, comment and review.

Information was carefully extracted from all eligible publications independently by two authors (D.W. and Z.Z.). For each included study, the following information was sought: the first author\'s last name, year of publication, country of origin, ethnicity, numbers of genotyped cases and controls, source of control groups (population- or hospital-based controls), genotyping methods, and quality control.

Statistical analysis {#s2b}
--------------------

For control group of each study, the allelic frequency was calculated and the observed genotype frequencies of the SNP rs17878362 were assessed for Hardy-Weinberg equilibrium using the χ^2^ test. The strength of the association between the SNP rs17878362 and breast cancer risk was measured by odds ratios (ORs) with 95% confidence intervals (CIs). We first estimated the risks of the variant Ins/Del and Ins/Ins genotypes on breast cancer, compared with the wild-type Del/Del homozygote, and then evaluated the risks of (Ins/Ins+Ins/Del) vs Del/Del and Ins/Ins vs (Ins/Del+Del/Del) on breast cancer, assuming dominant and recessive effects of the variant Ins allele, respectively. Stratified analyses were also performed by ethnicity, source of controls and sample size (≤500 and \>500 subjects).

For the heterogeneity test, a fixed-effect model (the Mantel-Haenszel method) [@pone.0061662-Mantel1] was used when *P*\>0.05, otherwise a random-effect model (the DerSimonian and Laird method) was used [@pone.0061662-DerSimonian1].

Cumulative meta-analysis were conducted to provide a framework for updating a genetic effect from all studies and to measure how much the genetic effect alters as evidence accumulates.

Sensitivity analyses were performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled OR. Funnel plots and Egger\'s linear regression tests were used to provide diagnosis of the potential publication bias [@pone.0061662-Egger1]. All analyses were done with Stata software (version 11.0; StataCorp LP, College Station, TX), using two-sided *P* values.

Results {#s3}
=======

Characteristics of studies {#s3a}
--------------------------

The flow chart in [Figure 2](#pone-0061662-g002){ref-type="fig"} summarizes the process of study selection. A total of 19 studies were retrieved based on the search criteria [@pone.0061662-Sjalander1]--[@pone.0061662-Cherdyntseva1]. Study characteristics are summarized in [Table 1](#pone-0061662-t001){ref-type="table"}. Among the 19 eligible case-control studies, there were 4479 breast cancer cases and 4683 controls. For race distribution, there were 6 studies of Europeans, 4 studies of Asians and 1 study with Africans. Breast cancers were confirmed histologically or pathologically in most studies. A classic polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was adopted in 16 of the 19 studies, however, only 37% of the included studies mentioned quality control on genotyping, such as randomly repeated assays or validation using other genotyping methods. The genotype distributions among the controls of all studies were in agreement with Hardy-Weinberg equilibrium except for two study [@pone.0061662-Sjalander1], [@pone.0061662-Faghani1].

![Flow diagram of the literature search.](pone.0061662.g002){#pone-0061662-g002}
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###### Main characteristics of selected studies.

![](pone.0061662.t001){#pone-0061662-t001-1}

  First author    Year       Country       Ethnicity   Sample size case/control   Source of controls   Genotyping method   Matching  
  -------------- ------ ----------------- ----------- -------------------------- -------------------- ------------------- ---------- -----
  Sjalander       1996       Sweden           ---              212/689                Population           PCR-RFLP          Yes      Yes
  Weston          1997       America       European             65/117                 Hospital            PCR-RFLP          Yes      Yes
  Wang-Gohrke     2002       Germany          ---              563/549                Population           PCR-RFLP          Yes      Yes
  Suspitsin       2003       Russia        European            529/249                 Hospital            PCR-RFLP          Yes      Yes
  Buyru           2007       Turkey           ---               115/63                Population           PCR-RFLP          Yes      Yes
  Zhang           2007        China          Asian              83/167                Population           PCR-RFLP          Yes      Yes
  Cavallone       2008       Canada        European            157/112                Population           Sequence           \-      Yes
  Costa           2008      Portugal          ---              261/656                 Hospital            PCR-RFLP          Yes      Yes
  Gaudet          2008       America          ---              578/390                Population           PCR-RFLP          Yes      Yes
  De Vecchi       2008        Italy           ---              350/352                 Hospital            PCR-RFLP           \-      Yes
  Akkiprik        2009       Turkey        European             97/107                Population            AS-PCR           Yes      Yes
  Hrstka          2009        Czech           ---              117/108                 Hospital            PCR-RFLP          Yes      Yes
  Ma              2009        China          Asian             117/123                 Hospital            PCR-RFLP          Yes      Yes
  Bisof           2010       Croatia          ---               95/108                Population            Taqman           Yes      Yes
  Trifa           2010       Tunisia        African            159/132                Population           PCR-RFLP           \-      Yes
  Jakubowska      2010       Poland        European            311/287                Population           PCR-RFLP          Yes      Yes
  Alawadi         2010   Syrians&Kuwaiti     Asian             229/133                 Hospital            PCR-RFLP          Yes      Yes
  Faghani         2011        Iran           Asian             145/145                Population           PCR-RFLP          Yes      Yes
  Cherdyntseva    2012       Russia        European            296/196                Population           PCR-RFLP          Yes      Yes

PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, allele specific- polymerase chain reaction.

Meta-analysis {#s3b}
-------------

Pooled ORs and heterogeneity test results for the association of SNP rs17878362 and breast cancer risk were shown in [Table 2](#pone-0061662-t002){ref-type="table"}. Overall, there was evidence of an association between the variant genotypes and the increased breast cancer risk in different genetic models. As shown in [Table 2](#pone-0061662-t002){ref-type="table"}, the variant genotypes (Del/Ins and Ins/Ins) were associated with a significantly increased risk of breast cancer in a dose-response manner compared with the wild-type Del/Del genotype (OR = 1.18, 95% CI: 1.00--1.40 for Del/Ins and 1.42, 1.09--1.84 for Ins/Ins; *P~t~* ~rend~\<0.001; [Figure 3](#pone-0061662-g003){ref-type="fig"} and [4](#pone-0061662-g004){ref-type="fig"}). In addition, significant main effects were also observed in dominant model (OR = 1.21, 95% CI = 1.03--1.41; [Figure 5](#pone-0061662-g005){ref-type="fig"}), but not in recessive model (OR = 1.28, 95% CI = 0.87--1.89; [Figure 6](#pone-0061662-g006){ref-type="fig"}). In the stratified analysis by ethnicity, no significant associations were not observed for any genetic models ([Table 2](#pone-0061662-t002){ref-type="table"}).

![Forest plot of breast cancer risk associated with the *p53* intron 3 16-bp duplication polymorphism (Del/Ins vs Del/Del).](pone.0061662.g003){#pone-0061662-g003}

![Forest plot of breast cancer risk associated with the *p53* intron 3 16-bp duplication polymorphism (Ins/Ins vs Del/Del).](pone.0061662.g004){#pone-0061662-g004}

![Forest plot of breast cancer risk associated with the *p53* intron 3 16-bp duplication polymorphism (Ins/Ins+Del/Ins vs Del/Del).](pone.0061662.g005){#pone-0061662-g005}

![Forest plot of breast cancer risk associated with the *p53* intron 3 16-bp duplication polymorphism (Ins/Ins vs Del/Del+Del/Ins).](pone.0061662.g006){#pone-0061662-g006}
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###### [Results](#s3){ref-type="sec"} of pooled ORs in the meta-analysis.

![](pone.0061662.t002){#pone-0061662-t002-2}

  Variables             N[a](#nt102){ref-type="table-fn"}   Del/Ins vs. Del/Del   Ins/Ins vs. Del/Del   Ins/Ins+Del/Ins vs. Del/Del   Ins/Ins vs. Del/Del+Del/Ins                                                    
  -------------------- ----------------------------------- --------------------- --------------------- ----------------------------- ----------------------------- ------------------- --------- ------------------- -------
  Total                                19                    1.18 (1.00--1.40)           0.001               1.42 (1.09--1.84)                   0.079              1.21 (1.03--1.41)    0.001    1.28 (0.87--1.89)   0.038
  Ethnicities                                                                                                                                                                                                        
  Asian                                 4                    1.76 (0.73--4.28)           0.001               0.53 (0.23--1.23)                    \-                1.67 (0.66--4.24)   \<0.001   0.43 (0.19--0.97)    \-
  European                              6                    1.04 (0.84--1.28)           0.273               1.07 (0.60--1.91)                   0.699              1.05 (0.84--1.32)    0.172    1.09 (0.62--1.92)   0.774
  African                               1                    1.20 (0.73--1.97)            \-                 0.88 (0.25--3.13)                    \-                1.16 (0.72--1.88)     \-      0.82 (0.23--2.91)    \-
  Source of controls                                                                                                                                                                                                 
  Population-based                     12                    1.23 (0.90--1.41)           0.001               1.26 (0.88--1.81)                   0.712              1.15 (0.92--1.43)    0.001    1.24 (0.86--1.77)   0.709
  Hospital-based                        7                    1.26 (0.99--1.61)           0.087               1.58 (0.75--3.34)                   0.008              1.25 (1.07--1.46)    0.141    1.47 (0.66--3.31)   0.002
  Sample size                                                                                                                                                                                                        
  ≤500                                 12                    1.31 (0.95--1.80)          \<0.001              1.20 (0.74--1.95)                   0.271              1.33 (0.98--1.81)   \<0.001   1.08 (0.67--1.75)   0.180
  \>500                                 7                    1.08 (0.96--1.22)           0.600               1.52 (1.11--2.08)                   0.065              1.12 (0.99--1.26)    0.525    1.49 (1.10--2.03)   0.057

Number of comparisons.

*P* value of Q-test for heterogeneity test. Random-effects model was used when *P*-value for heterogeneity test\<0.05; otherwise, fix-effects model was used.

Then, these studies were further divided into two subgroups according to their source of controls. A statistically significantly elevated risk was only found among hospital-based studies in the dominant model (OR = 1.25, 95% CI = 1.07--1.46; [Table 2](#pone-0061662-t002){ref-type="table"}).

When stratifying by sample size of studies, a significantly increased risk was also observed among large sample study (\>500 subjects) (homozygote model: OR = 1.52, 95% CI = 1.11--2.08; recessive model: OR = 1.49, 95% CI = 1.10--2.03) but not among small sample study (≤500 subjects).

Beginning with the first published study we computed the cumulative pooled OR by stepwise addition of the results of the other available studies up to the last one published in March 2012. In the cumulative meta-analysis, the pooled OR achieved significance starting in 2009 (*P* = 0.048) and showed a trend of association as published data accumulated (*P* = 0.017, [Figure 7](#pone-0061662-g007){ref-type="fig"}).

![Results of the cumulative meta-analysis (Ins/Ins+Del/Ins vs Del/Del).\
The random effects pooled OR with 95% CI at the end of each information step is shown.](pone.0061662.g007){#pone-0061662-g007}

Sensitivity analysis {#s3c}
--------------------

The leave-one-out sensitivity analysis indicated that the study by Faghani et al. [@pone.0061662-Faghani1] was the main source of heterogeneity, exclusion of which effectively abrogated the heterogeneity (Ins/Ins vs Del/Del+Del/Ins: *P* = 0.263 for heterogeneity). Although the genotype distribution in two studies [@pone.0061662-Sjalander1], [@pone.0061662-Faghani1] did not follow Hardy-Weinberg equilibrium, the corresponding summary ORs were not substantially altered with or without including these studies (data not shown), indicating that the results of this meta-analysis were statistically robust.

Publication bias {#s3d}
----------------

Funnel plots and Egger\'s tests were conducted to estimate the publication bias of literatures. The symmetry plots indicated that there was no publication bias in all pooled studies. The results were further confirmed by Egger\'s test (t = 0.150, *P* = 0.882 for Ins/Ins vs Del/Del; [Figure 8](#pone-0061662-g008){ref-type="fig"}).

![Funnel plot for publication bias test (Ins/Ins vs Del/Del).](pone.0061662.g008){#pone-0061662-g008}

Discussion {#s4}
==========

Our present meta-analysis incorporating 19 case-control studies (4479 cases and 4683 controls) examined the association between a commonly studied 16-bp duplication polymorphism within intron 3 of *p53* gene and breast cancer risk. The results showed that, in overall, the vaiant Ins allele was associated with a significantly increased risk of breast cancer. Given the important role of p53 in multiple cellular functions, such as DNA repair and apoptosis, it is biologically plausible that genetic variations of *p53* gene may modulate the risk of breast cancer.

It is reported that the 16-bp Ins allele was associated with lower level of *p53* transcript in lymphoblastoid cell lines, suggesting that this polymorphism causes an alteration in messenger RNA (mRNA) processing [@pone.0061662-Gemignani1]. Moreover, the intron 3 16-bp duplication polymorphism was in strong linkage disequilibrium with the well-studied codon 72 variant and investigators have showed that a *P53* haplotype (codon 72 Arg/Pro, intron 6 G\>A and intron 3 duplication) is associated with reduced apoptotic and DNA repair capacity in lymphoblastoid cell lines [@pone.0061662-Wu1]. These experimental data indicate that the *P53* variants may affect P53 function. Thus, it is reasonable that the 16-bp Ins allele might result in alteration of *p53* gene expression and function, leading to decrease of p53 mediated apoptosis of tumor cells. In our present meta-analysis, we found that individuals with the 16-bp Ins allele were associated with higher risk of breast cancer than subjects with the Del allele, which was consistent with experimental findings.

Our results showed that the Ins allele may increase risk of breast cancer, which were consistent with a previous meta-analysis of eight studies based on breast cancer [@pone.0061662-Hu1]. In the previous meta-analysis, however, the pooled sample size was relatively small and not enough information was available for more exhaustive subgroup analysis. Thereafter, several studies with a large sample size about this polymorphism on breast cancer risk have been reported, which would greatly improve the power of the meta-analysis of this polymorphism. Subgroup analyses performed by ethnicity, subject source, and sample size were also possible now. Thus, we updated this meta-analysis to derive a more precise estimation of these associations.

In our analysis, many studies did not provide the ethnic background of their participants, which precluded more detailed analysis of this polymorphism in different ethnicities. Thus, more specific ethnical information should be provided in further studies, which should lead to better understanding of the association between the 16-bp duplication polymorphism of p53 and breast cancer risk among different ethnicities.

We found an evidence for the association between the 16-bp Ins allele and breast cancer risk among large sample studies (\>500 subjects) but not among small sample studies (≤500 subjects). This is probably because studies with small sample size may have limited statistical power to detect a small effect or may have generated a fluctuated risk estimate. Thus, the use of a proper and large sample study is very crucial in reducing biases in such association studies.

In this meta-analysis, a thorough sensitivity analysis was carried out by removing each single study from pooled data and the results showed that there was no influence of the individual data on overall results. Moreover, we also calculated the overall pooled ORs on 16-bp duplication with and without the two largest studies [@pone.0061662-WangGohrke1], [@pone.0061662-Gaudet1], and in both instances, found that the 16-bp Ins allele was associated with the increased risk of breast cancer.

Some limitations of this meta-analysis should be acknowledged. First, in the subgroup analyses, the number of Africans and Asians was relatively small, not having enough statistical power to explore the real association. Second, misclassifications on disease status and genotypes may also influence the results, because cases in several studies were not confirmed by pathology, and the quality control of genotyping was also not well documented in several studies. In spite of these, our present meta-analysis also had some advantages. First, substantial number of cases and controls were pooled from different studies, which greatly increased statistical power of the analysis. Second, the quality of case-control studies included in this meta-analysis was satisfactory according to our selection criteria. Third, we did not detect any publication bias indicating that the whole pooled result should be unbiased.

Taken together, this meta-analysis provided evidence that the 16-bp duplication polymorphism within intron 3 of *p53* gene was significantly associated with an increased risk of breast cancer. Future well-designed large studies were warranted to validate these findings in different ethnic populations.
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